Advances in deep brain stimulation could lead to new treatments

Summary: Researchers discuss the potential of deep brain stimulation in the treatment of Parkinson’s disease, OCD, Tourette syndrome and other disorders.

Source: Wyss Center for Bio and Neuroengineering

A new paper published in Nature Reviews Neurology suggests that recent advances in deep brain stimulation (DBS) for Parkinson disease could lead to treatments for conditions such as obsessive-compulsive disorder (OCD), Gilles de la Tourette syndrome and depression. The authors of the paper, from the Geneva University Hospitals (HUG), University of Geneva, University of Tübingen and the Wyss Center for Bio and Neuroengineering, argue that bi-directional electrodes which can both stimulate and record from deep brain structures – known as closed-loop DBS – could have applications beyond Parkinson disease.

Other bi-directional brain-computer interfaces (BCIs) have been in development in recent years, notably for the real-time signal processing of neuronal activity to allow control of a robotic arm directly from the brain in people with paralysis.

Professor John Donoghue, Director of the Wyss Center: “Interestingly the fields of brain-computer interfaces for movement restoration and deep brain stimulation for Parkinson disease have developed largely independently. Deep brain stimulation researchers tend to be neurologists or neurosurgeons while brain-computer interface researchers are often neuroscientists, roboticists and engineers. By working together and sharing information we can learn from each other and potentially expand the reach of this technology so that it can help more people.”

DBS is typically used to relieve the shaking and rigidity associated with Parkinson disease. Although it has been tried in more than 40 other brain targets, very few other disease indications for the treatment have been established. The latest closed-loop DBS systems sense changes in the brain following stimulation and automatically adapt the level of the next stimulating pulse accordingly. This adjustment in the way that stimulation is delivered allows for tailored, accurate treatment that may prove suitable for other disorders.

Other areas that might benefit from closed-loop DBS include OCD – although early trials indicate that there may be a time delay before improvements are seen, Gilles de la Tourette syndrome – for the treatment of both movement tics and psychiatric symptoms, and depression – although early trials indicate that the exact position of the electrodes and stimulation parameters are critical.

This shows a drawing of neurons
Cortical and subcortical motor neurons (red) and affective neurons (green). The image is credited to Wyss Center.

The authors warn against the use of DBS for purposes beyond disease and call for strong ethical standards that require both artificial intelligence and neural interfaces to respect and preserve people’s privacy, identity, agency and equality.

Neurostimulators with sensing capabilities are still in their infancy. They have still only been used in research settings and so closed-loop DBS is not yet a long-term treatment solution for Parkinson disease, or any other disorder. These new systems will however soon become commercially available and when they do they will bring with them new treatment possibilities and new hope.

These questions will be discussed at OptoDBS2019, the third edition of an international meeting held at Campus Biotech, Geneva later this year.

About this neuroscience research article

Wyss Center for Bio and Neuroengineering
Media Contacts:
Jo Bowler – Wyss Center for Bio and Neuroengineering
Image Source:
The image is credited to Wyss Center.

Original Research: Closed access
“Biomarkers for closed-loop deep brain stimulation in Parkinson disease and beyond”Nature Reviews Neurology (2019) doi:10.1038/s41582-019-0166-4


Biomarkers for closed-loop deep brain stimulation in Parkinson disease and beyond

Subthalamic deep brain stimulation (DBS) for Parkinson disease (PD) currently requires laborious open-loop programming, which can mitigate the benefits of this treatment. Experimental closed-loop DBS systems are emerging that can sense the electrophysiological surrogates of PD motor signs and respond with delivery of an automatically adapted stimulation. Such biomarker-based neural interfaces constitute a major advance towards improving the outcomes of patients treated with DBS and enhancing our understanding of the pathophysiological mechanisms underlying PD. In this Perspectives article, we argue that closed-loop DBS, in addition to offering advantages in patients with PD, might extend the current indications for DBS to include selected psychiatric disorders in which the symptoms are similarly driven by pathological brain circuit activity. The success of closed-loop DBS in such settings will depend on the identification of symptom-specific biomarkers, which ideally should reflect causal mechanisms of the underlying pathology.

Feel free to share this Neuroscience News.
Join our Newsletter
I agree to have my personal information transferred to AWeber for Neuroscience Newsletter ( more information )
Sign up to receive our recent neuroscience headlines and summaries sent to your email once a day, totally free.
We hate spam and only use your email to contact you about newsletters. You can cancel your subscription any time.